Advanced Solid Tumors Clinical Trials in Irving, Texas

11 studies are recruiting for advanced solid tumors in Irving, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Dallas, Irving, Texas

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

2. A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

   Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main g…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology ( Site 1012), Irving, Texas

   Locations

   49 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06818643 on ClinicalTrials.gov

3. A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

   This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   33 in total

   Run by

   CStone Pharmaceuticals

   See if you can join NCT06741644 on ClinicalTrials.gov

4. Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

   The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   8 in total

   Run by

   Gilead Sciences

   See if you can join NCT06167317 on ClinicalTrials.gov

5. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

   This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Dallas, Irving, Texas

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06384352 on ClinicalTrials.gov

6. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Dallas, Irving, Texas

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

7. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07397338 on ClinicalTrials.gov

8. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

   A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   26 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT05954312 on ClinicalTrials.gov

9. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

   The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   7 in total

   Run by

   Tagworks Pharmaceuticals BV

   See if you can join NCT06959706 on ClinicalTrials.gov

10. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

    A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Dallas, Irving, Texas

    Locations

    9 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT06804824 on ClinicalTrials.gov

11. PAS-004 in Patients With Advanced Solid Tumors

    The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate diff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Irving, Texas

    Locations

    7 in total

    Run by

    Pasithea Therapeutics Corp.

    See if you can join NCT06299839 on ClinicalTrials.gov